NuvOx Therapeutics ^{Filed Terms, NYSE American: NUOX}

We are a clinical-stage biopharmaceutical company developing innovative oxygen therapeutic solutions for the treatment of diseases where hypoxia, or lack of oxygen, plays a critical role. Our product candidate is NanO2, the API of which is dodecafluoropentane. NanO2™ is administered intravenously as an emulsified liquid, containing nano-sized droplets that after entering the body, due to the human body temperature, convert to a gas, which enables them to deliver more oxygen than when in the liquid state. Due to the fact that the size of the NanO2 particle is approximately 30 times smaller in diameter than a red blood cell, the NanO2 particle can partition into tissue, deliver oxygen and further facilitate oxygen transfer from red blood cell to tissue. The focus of our clinical research and development to date has been on the administration of NanO2 to treat acute ischemic stroke, GBM, ARDS, and sickle cell anemia. In each of these diseases or conditions, lack of oxygen plays a critical role in either weakening the effectiveness of standard treatment or directly causing mortality or morbidity. We have completed an open-label Phase Ib/IIa human clinical trial of NanO2 for the treatment of GBM in 11 patients in Australia and a randomized, placebo-controlled Phase Ib/IIa clinical trial of NanO2 in the United States for the treatment of acute ischemic stroke in 24 patients.